...
首页> 外文期刊>Physiological Reports >The impact of the glucagon‐like peptide 1 receptor agonist liraglutide on the streptozotocin‐induced diabetic mouse kidney proteome
【24h】

The impact of the glucagon‐like peptide 1 receptor agonist liraglutide on the streptozotocin‐induced diabetic mouse kidney proteome

机译:胰高血糖素样肽1受体激动剂利拉鲁肽对链脲佐菌素诱导的糖尿病小鼠肾脏蛋白质组的影响

获取原文
           

摘要

In diabetes mellitus (DM), the kidneys are exposed to increased levels of hyperglycemia‐induced oxidative stress. Elevated amounts of reactive oxygen species (ROS) are believed to provoke ultrastructural changes in kidney tissue and can eventually result in DM late complications such as diabetic nephropathy. While it is reported that glucagon‐like peptide 1 receptors (GLP‐1R) are present in the kidney vasculature, the effects of GLP‐1 on the kidney proteome in DM is not well described. Thus, we set out to investigate potential effects on the proteomic level. Here the effects of GLP‐1R agonism using the GLP‐1 analogue liraglutide are studied in the kidneys of streptozotocin (STZ)‐treated mice ( n? =?6/group) by label‐free shotgun mass spectrometry (MS) and targeted MS. Unsupervised and supervised multivariate analyses are followed by one‐way ANOVA. Shotgun MS data of vehicle and liraglutide‐treated mouse groups are separated in the supervised multivariate analysis and separation is also achieved in the subsequent unsupervised multivariate analysis using targeted MS data. The mouse group receiving the GLP‐1R agonist liraglutide has increased protein abundances of glutathione peroxidase‐3 (GPX3) and catalase (CATA) while the abundances of neuroplastin (NPTN) and bifunctional glutamate/proline–tRNA ligase (SYEP) are decreased compared to the STZ vehicle mice. The data suggest that GLP‐1R agonism mainly influences abundances of structurally involved proteins and proteins involved in oxidative stress responses in the STZ mouse kidney. The changes could be direct effects of GLP‐1R agonism in the kidneys or indirectly caused by a systemic response to GLP‐1R activation.
机译:在糖尿病(DM)中,肾脏暴露于高血糖引起的氧化应激水平升高。活性氧(ROS)的增加被认为会引起肾脏组织的超微结构变化,并最终导致DM晚期并发症,例如糖尿病性肾病。据报道,肾血管中存在胰高血糖素样肽1受体(GLP-1R),但对DM中肾蛋白质组的作用,GLP-1的描述却不多。因此,我们着手研究对蛋白质组学水平的潜在影响。在这里,通过无标记shot弹枪质谱(MS)和靶向MS在链脲佐菌素(STZ)处理的小鼠(n?=?6 /组)的肾脏中研究了使用GLP-1类似物利拉鲁肽的GLP-1R激动作用。 。在无监督和有监督的多元分析之后,进行单向方差分析。媒介物和利拉鲁肽治疗的小鼠组的Shotgun MS数据在有监督的多变量分析中分离,并且在随后的无监督多变量分析中也使用目标MS数据实现了分离。与GLP-1R激动剂利拉鲁肽相比,小鼠组的谷胱甘肽过氧化物酶-3(GPX3)和过氧化氢酶(CATA)的蛋白丰度增加,而神经增塑剂(NPTN)和双功能谷氨酸/脯氨酸-tRNA连接酶(SYEP)的丰度降低STZ载具小鼠。数据表明,GLP-1R激动作用主要影响STZ小鼠肾脏中结构涉及的蛋白质和参与氧化应激反应的蛋白质的丰度。这些变化可能是肾脏中GLP-1R激动作用的直接作用,也可能是由对GLP-1R激活的系统反应间接引起的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号